Dayvigo (Lemborexant) Cost in Maryland: Prices, Insurance, and Savings for 2026

What Dayvigo Actually Costs at Maryland Pharmacies in 2026

The average cash-pay price for a 30-day supply of Dayvigo across Maryland retail pharmacies sits near $85 per month in 2026. That figure reflects negotiated rates through discount programs and pharmacy benefit middlemen, not Eisai's wholesale acquisition cost (WAC) of $320 per month. The spread between WAC and what patients actually hand over at the counter is wider for Dayvigo than for many branded sleep medications, partly because Eisai has maintained aggressive coupon and copay-card programs since the drug's FDA approval in December 2019.

Prices vary by pharmacy. A CVS or Walgreens in Baltimore may quote $90 to $110 without a coupon, while independent pharmacies in smaller Maryland counties sometimes price lower due to different purchasing group agreements. Costco pharmacies (no membership required for the pharmacy counter in Maryland) tend to post among the lowest retail prices statewide. Patients filling at mail-order pharmacies such as Express Scripts or OptumRx often see even deeper discounts when their plan has a preferred mail-order tier. The key variable is not the pharmacy itself but whether the patient has commercial insurance, Medicaid, Medicare Part D, or no coverage at all [1].

Maryland Medicaid Coverage for Dayvigo

Maryland Medicaid does cover Dayvigo, but the state requires prior authorization (PA) before approving the claim. The PA process typically requires documentation that the patient has tried and failed, or has a contraindication to, a first-line generic sleep agent such as zolpidem or eszopiclone. Maryland's Medicaid Pharmacy Program follows the recommendations of the state's Drug Use Review Board, which classified Dayvigo as a non-preferred brand requiring step therapy [2].

To satisfy the PA, prescribers submit evidence of at least one prior trial of a generic hypnotic. In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly improved both sleep onset and sleep maintenance compared to placebo in adults aged 55 and older, with latency to persistent sleep reduced by 10.5 and 12.6 minutes, respectively, versus placebo [3]. Citing this trial data can strengthen a PA appeal for patients who respond poorly to GABA-A modulators.

Once approved, the Medicaid copay for Dayvigo in Maryland is typically $0 to $3 depending on the patient's income tier. The PA is usually valid for 12 months before renewal documentation is needed. Denials can be appealed through the Maryland Department of Health's fair hearing process, and turnaround on initial PA decisions averages 24 to 72 hours.

How Insurance Plans Handle Dayvigo in Maryland

Commercial insurers in Maryland vary widely in how they tier Dayvigo. CareFirst BlueCross BlueShield, the state's largest insurer, places Dayvigo on a non-preferred brand tier (Tier 3 or Tier 4 depending on the specific plan). UnitedHealthcare and Aetna plans sold on the Maryland Health Benefit Exchange generally require step therapy through a generic Z-drug before authorizing Dayvigo. Cigna plans in Maryland have historically placed DORAs on a specialty tier, though that classification has shifted toward standard brand tiers in some 2026 plan designs.

For Medicare Part D enrollees, Dayvigo coverage depends on the specific Part D formulary. Many Part D plans cover it with a PA and place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect in 2025, Maryland Medicare beneficiaries now face a hard ceiling on total drug spending, which can significantly reduce the real cost of branded medications like Dayvigo for patients taking multiple prescriptions [4].

A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that prior authorization requirements for DORAs resulted in approximately 30% of initial claims being rejected, though 68% of those were ultimately approved on appeal [5]. Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, has noted: "Prior authorization for newer insomnia medications creates a real barrier for patients who have already failed first-line treatments. The step-therapy model doesn't always reflect the clinical reality that some patients need a mechanistically different approach from the start."

The Eisai Savings Card: How It Works in Maryland

Eisai offers a manufacturer copay savings card for Dayvigo that can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The card covers up to $150 per 30-day fill, with a maximum annual benefit of $1,800. Patients activate the card through Eisai's Dayvigo website or by calling the number on the card provided by their prescriber.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or any other government-funded plan). Maryland residents with commercial coverage who face a $50 Tier 3 copay, for instance, would pay $0 after applying the savings card. Those with a $200 copay on a Tier 4 plan would pay $50 ($200 minus the $150 card maximum).

The card works at the point of sale. The pharmacist processes it as a secondary claim after the primary insurance adjudicates. There is no income requirement. One limitation: the savings card cannot be combined with 340B pricing, and Maryland pharmacies participating in the 340B program must process claims under one program or the other.

Compounded Lemborexant in Maryland: Legality and Access

Compounded lemborexant is available in Maryland through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound medications based on a valid patient-specific prescription when a prescriber determines that a commercially available product does not meet the patient's needs [6]. Maryland's Board of Pharmacy permits 503A compounding and maintains its own inspection and licensing standards for these facilities.

Common clinical reasons for compounding lemborexant include dose customization (for example, a 2.5 mg dose not commercially available), allergen-free formulations for patients with sensitivities to inactive ingredients in the branded tablet, or liquid preparations for patients who cannot swallow tablets. The cost of compounded lemborexant varies. Some 503A pharmacies advertise prices near $40 to $60 per month, though pricing is not standardized and depends on the compounding pharmacy's sourcing costs for the active pharmaceutical ingredient (API).

A critical distinction: 503A-compounded lemborexant is not FDA-approved and does not carry the same regulatory assurance of bioequivalence as Eisai's Dayvigo tablets. The American Academy of Sleep Medicine (AASM) has not issued specific guidance on compounded DORAs, but the organization's 2023 clinical practice guideline on insomnia pharmacotherapy emphasizes using FDA-approved formulations when available. Patients considering compounded alternatives should discuss bioavailability and quality assurance with their prescriber.

Dayvigo via Telehealth in Maryland

Maryland permits telehealth prescribing of Dayvigo. The state's telehealth parity law (Maryland Code, Health-General § 15-105.2) requires insurers to cover telehealth visits at the same rate as in-person visits and does not restrict the prescribing of Schedule IV controlled substances via telehealth, provided the prescriber holds an active Maryland license and establishes a valid prescriber-patient relationship [7].

Since the DEA finalized its post-pandemic telehealth prescribing rule in 2025, Schedule IV medications like Dayvigo can be prescribed via audio-video telehealth without a prior in-person examination, as long as the encounter meets DEA standards for a legitimate medical evaluation. This applies to both initial prescriptions and refills.

HealthRX and other telehealth platforms operating in Maryland can evaluate patients for insomnia, prescribe Dayvigo when clinically appropriate, and transmit the prescription electronically to the patient's preferred Maryland pharmacy. The entire process, from evaluation to pharmacy pickup, can take as little as 24 to 48 hours for straightforward cases.

How Dayvigo Compares to Other Insomnia Drugs on Cost

Dayvigo's $85 average cash-pay price in Maryland is higher than generic alternatives but competitive among branded insomnia medications. Generic zolpidem (Ambien) costs $8 to $15 per month at most Maryland pharmacies. Generic suvorexant, the other DORA on the market, is not yet available because Merck's patent on Belsomra extends through 2029. Branded Belsomra runs approximately $380 to $420 per month at Maryland retail pharmacies, making Dayvigo the less expensive branded DORA option.

The SUNRISE-2 trial (N=949), a 12-month study comparing lemborexant to placebo, demonstrated sustained efficacy on both subjective sleep onset latency and wake after sleep onset, with no evidence of rebound insomnia or withdrawal symptoms upon discontinuation [8]. This long-term safety and efficacy profile may justify the higher cost relative to generic Z-drugs for patients who need ongoing treatment. Dr. Andrew Krystal, professor of psychiatry at the University of California, San Francisco, and a SUNRISE-2 investigator, has stated: "The DORA mechanism offers a fundamentally different approach to insomnia by reducing wakefulness drive rather than sedating the brain. For patients who experience next-day grogginess or complex sleep behaviors on traditional hypnotics, this distinction matters clinically."

Generic lemborexant is not expected before 2032, when Eisai's key patents expire. Until then, the savings card and insurance negotiations represent the primary cost-reduction pathways for Maryland patients.

Discount Programs and Additional Savings Options

Beyond the Eisai savings card, Maryland patients have several other avenues to reduce Dayvigo costs:

GoodRx, RxSaver, and similar aggregators. These platforms negotiate cash-pay rates with pharmacy chains and may offer Dayvigo for $75 to $95 at Maryland locations. Prices change frequently, so checking multiple platforms before each fill is worth the two minutes.

Patient assistance programs (PAPs). Eisai's Dayvigo Patient Assistance Program provides free medication to uninsured patients who meet income guidelines (generally at or below 400% of the federal poverty level). Maryland residents apply directly through Eisai's website with proof of income and a prescription.

Maryland Pharmacy Discount Program (MPDP). The state-run discount card program, available to all Maryland residents regardless of insurance status, provides negotiated rates on prescription drugs at participating pharmacies. The MPDP discount on Dayvigo varies by pharmacy but typically falls in the $80 to $100 range.

340B-eligible health centers. Federally Qualified Health Centers (FQHCs) in Maryland, including those in the Baltimore metro area and on the Eastern Shore, can dispense Dayvigo at 340B pricing if the patient is a registered patient of the center. This pricing is often the lowest available, though exact amounts are not publicly disclosed [9].

Tips for Maryland Patients Starting Dayvigo

The FDA-approved starting dose is 5 mg taken once nightly, no more than 7 minutes before bed, on an empty stomach or at least 2 hours after a meal. The dose may be increased to 10 mg if the 5 mg dose is well tolerated but insufficiently effective. Patients with moderate hepatic impairment should not exceed 5 mg [1].

Before filling, ask the prescriber's office to run a prior authorization if you have insurance. Request the Eisai savings card at the same appointment. If the PA is denied, ask the prescriber to submit an appeal with documentation of failed trials on generic agents. Maryland law requires insurers to process standard PAs within 2 business days and urgent PAs within 24 hours.

The most common adverse effects in clinical trials were somnolence (reported by 7% on 5 mg, 10% on 10 mg vs. 1% placebo), headache, and abnormal dreams [1]. Sleep paralysis and hypnagogic hallucinations occurred rarely (under 1%) but should be reported to the prescriber immediately.

Patients aged 65 and older represented a large portion of the SUNRISE-1 population, and no dose adjustment is required based on age alone. The trial specifically demonstrated that lemborexant 5 mg reduced latency to persistent sleep by 10.5 minutes versus placebo (P<0.001) in this older population, a clinically meaningful improvement for a group that often metabolizes sedative-hypnotics more slowly [3].